A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Clinical trial NCT00286806 · COMPLETED

Trial details

NCT number: NCT00286806
Sponsor: Ascenta Therapeutics
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hormone Refractory Prostate Cancer

Start date: 2005-12-01
Primary completion: 2007-06-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.